Argenx saw a tremendous uplift in Q3, hitting an all-time high of $555.55 and had its price target raised to $635 by Citi. A substantial portion of this growth is associated with its groundbreeaking antibody drug Vyvgart that was approved by the FDA for a rare nerve disease and holds promising results for autoimmune diseases. Its license with Halozyme Therapeutics was expanded, adding 4 new targets for $30M and proving strategic impact for Argenx. Despite upcoming competition from J&J's Myasthenia Gravis Filing for Nipocalimab, Argenx appears solid grounded with boosted sales and financial performance amid clinical plans for Vyvgart. The company is scheduled to present at upcoming investor conferences, indicative of their success and strong market following. At 'Vision 2030', the company disclosed plans for continuous innovation targeting novel solutions. Argenx also announced the approval of Vyvgart injection for Generalized Myasthenia Gravis in association with Zai Lab in China, adding another feather in their cap. It's notable that argenx reports strong full year 2024 financial results but its late-stage trial for efgartigimod flopped in patients with pemphigus stirring some concern.
argenx News Analytics from Thu, 16 Nov 2023 08:00:00 GMT to Fri, 18 Oct 2024 16:44:29 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -2
